FDA unveils pathway for ultra-rare disease therapies
The FDA has released draft guidance outlining an approval pathway for individualized therapies aimed at ultra-rare diseases, building on a framework first outlined by agency leaders in November. The proposed pathway, dubbed the “Plausible Mechanism Framework,” would allow sponsors to pursue approval for gene-editing and RNA-based treatments when traditional randomized trials are not feasible because […]
Continue Reading